What is the 13F Pro Quality Score for ELVN?

13F Pro ranks Enliven Therapeutics, Inc. (ELVN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELVN's current score at https://13fpro.ai/research/ELVN (free sign-up required for the full ranking).

Which hedge funds own the most ELVN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ELVN include ORBIMED ADVISORS, FMR, Polar Capital Holdings Plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ELVN as soon as new 13F filings post.

Where does 13F Pro source ELVN data?

All Enliven Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Enliven Therapeutics, Inc. files with the SEC under CIK 1672619. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELVN in?

Enliven Therapeutics, Inc. (ELVN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELVN research updated on 13F Pro?

ELVN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Enliven Therapeutics, Inc.(ELVN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1672619 ELVN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ELVN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Enliven Therapeutics, Inc. (ELVN), a Healthcare sector company. ELVN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Enliven Therapeutics, Inc. reports net income of $-23.6M, free cash flow of $-19.3M. Top institutional holders of ELVN by reported 13-F value include ORBIMED ADVISORS, FMR, Polar Capital Holdings Plc, based on the most recent SEC filings. ELVN trades on the Nasdaq exchange and files with the SEC under CIK 1672619. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enliven Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-23.6M

Free Cash Flow

Q1 2026

$-19.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-175.3% YoY

$-103.7MFY 2025

FY19 $-23.5MFY22 $-37.7MFY25 $-103.7M

Operating Income

-208.5% YoY

$-119.7MFY 2025

FY19 $-24.1MFY22 $-38.8MFY25 $-119.7M

EPS (Diluted)

+84.8% YoY

$-1.83FY 2025

FY19 —FY22 $-12.05FY25 $-1.83

Total Assets

+471.6% YoY

$476.2MFY 2025

FY19 $33.3MFY22 $83.3MFY25 $476.2M

Op. Cash Flow

-119.2% YoY

$-70.3MFY 2025

FY19 $-21.9MFY22 $-32.1MFY25 $-70.3M

Metric	FY 2025	FY 2022	FY 2019
Net Income	$-103.7M -175.3%	$-37.7M -60.5%	$-23.5M
Operating Income	$-119.7M -208.5%	$-38.8M -60.9%	$-24.1M
EPS (Diluted)	$-1.83 +84.8%	$-12.05	—
Total Assets	$476.2M +471.6%	$83.3M +150.2%	$33.3M
Operating Cash Flow	$-70.3M -119.2%	$-32.1M -46.6%	$-21.9M

AI Insight: ELVN Financial Trends

Enliven remains a pre-revenue clinical-stage burner; equity base grew to $453M but cash consumption persists with no revenue in sight.

• No revenue recorded across all eight quarters from Q2 2024 through Q1 2026, confirming purely clinical-stage status.

• Equity jumped from $288M in Q1 2025 to $488M in Q2 2025, suggesting a capital raise, then declined to $453M by Q1 2026.

• Operating losses widened to -$34M in Q4 2025, the steepest quarter recorded, before easing slightly to -$28M in Q1 2026.

⚠ Operating cash burn of -$19M in Q1 2026 with equity eroding each quarter; runway duration is the key variable to monitor.

⚠ Any first revenue recognition would be a pivotal inflection; continued silence on revenue signals ongoing pre-commercial stage.

AI Insight: ELVN Ratio Trends

ELVN's capital returns remain deeply negative but have improved meaningfully from Q1 2025 trough, with ROIC recovering from -44.0% to -24.6% by Q1 2026.

• ROIC improved sharply from its Q1 2025 trough of -44.0% to -24.6% in Q1 2026, a ~19pp recovery over four quarters.

• ROA followed the same trajectory, improving from -37.7% in Q1 2025 to -20.3% in Q1 2026, suggesting better capital deployment efficiency.

• OpMargin, NPM, and D/E remain entirely unreported across all periods, limiting visibility into profitability and leverage structure.

⚠ ROIC deteriorated from -23.4% in Q2 2025 to -29.8% in Q4 2025 before recovering — quarterly volatility signals burn-rate unevenness.

⚠ All returns remain deeply negative; any pipeline setback could reverse the improving trend and accelerate cash depletion.

Get alerted when ELVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Enliven Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELVN

ORBIMED ADVISORS LLC
$312.0M7,959,538 sh
FMR LLC
$267.7M6,829,246 sh
Polar Capital Holdings Plc
$198.6M5,065,933 sh
BlackRock, Inc.
$144.4M3,684,707 sh
Commodore Capital LP
$128.4M3,275,000 sh
Vestal Point Capital, LP
$127.4M3,250,000 sh
Bellevue Group AG
$91.0M2,320,867 sh
Fairmount Funds Management LLC
$72.7M1,855,644 sh
CITADEL ADVISORS LLC
$68.4M1,743,915 sh
VR Adviser, LLC
$67.7M1,726,331 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$312.0M	7,959,538
FMR LLC	$267.7M	6,829,246
Polar Capital Holdings Plc	$198.6M	5,065,933
BlackRock, Inc.	$144.4M	3,684,707
Commodore Capital LP	$128.4M	3,275,000
Vestal Point Capital, LP	$127.4M	3,250,000
Bellevue Group AG	$91.0M	2,320,867
Fairmount Funds Management LLC	$72.7M	1,855,644
CITADEL ADVISORS LLC	$68.4M	1,743,915
VR Adviser, LLC	$67.7M	1,726,331

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELVN on your watchlist

Track score changes the day Enliven Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELVN a good stock to buy?

13F Pro's AI-powered analysis of Enliven Therapeutics, Inc. (ELVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELVN are available on the ELVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ELVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Enliven Therapeutics, Inc.'s investment landscape.